Peptide Therapeutics Market - By Type (Branded, Generic), By Application (Metabolic, Cancer, Cardiovascular, Gastrointestinal), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital, Retail)- Global Forecast 2023 to 2032

Industry Analysis

Peptide Therapeutics Market size was evaluated to be around USD 47.67 billion in 2022 and is projected to expand at over 6.9% CAGR from 2023-2032 due to high prevalence of chronic and metabolic diseases along with high demand for novel therapeutics.
 

To get more details on this report: Request Free Sample PDF
 

Peptides are short chains of amino acids that are linked by peptide bonds. They are a unique class of compounds with therapeutic applications and play an important role within the cells, from signalling to anti-infectives. Peptide therapeutics act as essential replacement therapies that supplement peptide hormones when inadequate endogenous levels occur. Due to continuous research and development, the utilization of peptide therapeutics has evolved over time. Since the development of the first peptide therapeutic, insulin has showcased remarkable outcomes, which led to more research, development, and approval of around 80 peptide therapeutics all over the world.
 

COVID-19 Impact

COVID-19 has moderately impacted the growth of the peptide therapeutics market worldwide. Due to the therapeutic effect of peptide drugs, many of the peptide-based vaccines for the treatment of COVID-19 were in clinical trials. The continuous support and investments of the government in the research and development of peptide therapeutics will help expand this market. Around 21 peptide drugs, among which 15 are synthetic peptide drugs, were in development for treating acute respiratory distress syndrome (ARDS) and other respiratory issues caused by the SARS-CO-2 infection.
 

Peptide Therapeutics Market Trends

Cancer has become one of the leading causes of death worldwide. According to the GLOBOCAN report, in 2020, 19.3 million new cases of cancer were diagnosed, among which 10 million patients died due to cancer. The GLOBOCAN report predicts that in 2040, this number will grow and reach 28.4 million cancer cases all over the globe. Peptide therapeutics have emerged as a novel and promising treatment option for solid tumours like breast cancer. owing to the advantages of peptide therapeutics such as ease of synthesis, high target specificity and selectivity, and low toxicity, researchers have been focusing on developing novel and effective peptide therapeutics for many diseases, including cancer.
 

The prevalence of metabolic disorders is increasing all over the globe, leading to an growing demand for peptide therapeutics. Diabetes is one of the most common metabolic disorders that is treated using the peptide therapeutic insulin. Metabolic disorders and cancer are the main disease areas driving the utilisation of therapeutic drugs globally. According to International Diabetes Federation, in 2021, approximately 537 million adults are suffering from diabetes. The growing geriatric population, along with the increase in the incidence rate of infectious diseases, cardiovascular, respiratory, and other immune disorders, will propel the market trends.
 

The increased investments in developing novel therapeutics will boost this market. Increasing research and development in developing peptide therapeutics mainly focuses on oncology, metabolic disorders, and infectious diseases. The key players in this market are taking initiatives and investing more in the R&D of new drugs to retain their positions and develop novel drugs with higher efficacy to treat target diseases. Clinical trials related to such therapeutics have increased over the past decades.
 

Peptide Therapeutics Type Segmentation

To get more details on this report: Request Free Sample PDF
 

Based on type, the peptide therapeutics market is subdivided into branded and generic peptide. The branded peptide segment dominates the market in 2022 with revenue share of 61%. The prominent players in pharmaceutical industry are increasing the R&D investments and developing new drugs with higher prescription rates. In the coming years, generic peptides segment is expected to grow at higher pace due to the increasing healthcare expenditure and increased federal government healthcare spendings. The loss of patent is seen as an opportunity for generic segment to grow in this market.
 

Peptide Therapeutics Application Segmentation

Based on applications, the peptide therapeutics market is classified into metabolic disorders, cancer, cardiovascular, gastrointestinal, central nervous system, infectious diseases, respiratory disorders, pain management, renal disorders, dermatology, and other applications. The metabolic disorders segment accounted for the largest share in 2022 due to the high prevalence of metabolic diseases such as diabetes. During the forecast period, the cancer segment is expected to grow at a higher rate due to the increasing cases of cancer worldwide and the escalated utilisation of peptide therapeutics for treating cancer.
 

The increased demand for effective treatment options for treating diseases will boost this market. Increased awareness of the side effects of radiation and chemotherapy among patients has driven attention to peptide therapeutics, which have low toxicity. Hence, these factors will support the segment share.
 

Peptide Therapeutics Route of Administration Segmentation

Based on route of administration the peptide market is subdivided parenteral, oral, and other routes of administration. Parenteral segment held highest revenue share of market in 2022. This attributes to the factors like fast drug delivery, high adoption rate, and ease of administration.
 

Peptide Therapeutics Manufacturer Type Segmentation

To get more details on this report: Request Free Sample PDF
 

Based on manufacturer type, the peptide therapeutics market is classified into in-house and outsourced. The in-house segment dominated the market with the highest market share of around 68% in 2022 and is expected to grow at the highest CAGR during the forecast period. The key players are involved in developing the peptide therapeutics in-house because of the high cost associated with outsourcing and strict regulation.
 

Peptide Therapeutics Synthesis Technology Segmentation

Based on synthesis technology, the peptide therapeutics market is subdivided into liquid-phase peptide synthesis, solid-phase peptide synthesis, and hybrid technology. The liquid-phase peptide synthesis segment held the majority of market share in 2022. The high demand for pure peptides for developing effective therapeutics has facilitated the segment landscape. A significant growth in solid-phase peptide synthesis is expected as it lowers the synthesis time required for the production of peptides.
 

Peptide Therapeutics Distribution Channel Segmentation

Based on distribution channel, the global peptide market is segmented into hospital, retail, and online pharmacies. The hospital pharmacies segment dominated the global market in 2022. As hospital pharmacies are primarily responsible for the availability of all the medications required in hospital.
 

Peptide Therapeutics Market Regional Analysis

Based on region, global peptide therapeutics market is subdivided into North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa. In 2022, the North America held the highest revenue in this market, owing to an increased prevalence of chronic diseases like cancer and diabetes, increasing investments for R&D for developing novel therapeutics, presence of key players, and increased healthcare expenditure are the factors contributing the growth of this segment.
 

Peptide Therapeutics Industry Leaders

The key players in peptide therapeutics market are Pfizer, Inc., Amgen, Inc., Bachem Holding AG, Eli Lilly and Company, Sanofi, AstraZeneca plc, AbbVie, GlaxoSmithKline plc, Baush Health, and Lonza Inc. These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
 

Peptide Therapeutics Industry News:

• In March 2023, Sanofi cut the price of its widely used insulin Lantus in the U.S. by 78% with a cap of 35 USD for all the patients with commercial insurance in order to make the out-of-pocket medications affordable.
   
• In March 2023, Pfizer has invested 43 USD billion for cancer research & development.
   

The peptide therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type

• Branded peptides
• Generic peptides

By Application

• Metabolic disorders
• Cancer
• Cardiovascular disorders
• Gastrointestinal disorders
• Central nervous system disorders
• Infectious diseases
• Respiratory disorders
• Pain management
• Renal disorders
• Dermatology
• Other applications

By Route of Administration

• Parenteral
• Oral
• Other routes of administration

By Manufacturer Type

• In-house
• Outsourced

By Synthesis Technology

• Liquid phase peptide synthesis (LPPS)
• Solid phase peptide synthesis (SPPS)
• Hybrid Technology
  By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA